With 0.65 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.5 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $1.96 whereas the lowest price it dropped to was $1.73. The 52-week range on BGMS shows that it touched its highest point at $213.60 and its lowest point at $1.61 during that stretch. It currently has a 1-year price target of $240.00. With its current market cap of 4.17 million, BGMS has annualized dividend of $36.00 while the current yield stands at 1935.48%. Beta for the stock currently stands at 0.05.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of BGMS was down-trending over the past week, with a drop of -4.62%, but this was down by -61.09% over a month. Three-month performance dropped to -77.34% while six-month performance fell -97.41%. The stock lost -97.94% in the past year, while it has lost -98.82% so far this year.
Float and Shares Shorts:
At present, 1.58 million BGMS shares are outstanding with a float of 1.07 million shares on hand for trading. On 2025-10-15, short shares totaled 0.11 million, which was 386.99999999999994 higher than short shares on 1757894400. In addition to Dr. Sing Ee Wong as the firm’s Chairman, CEO & President, Mr. Cu Seng Kiu serves as its Executive Director, CFO & Secretary.
Institutional Ownership:
Through their ownership of 0.0063300002 of BGMS’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-06-30, BGMS reported revenue of $0.0 and operating income of -$1317000.0. The EBITDA in the recently reported quarter was -$1313000.0 and diluted EPS was -$14.7.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. The surprise factor in the prior quarter was -$344.4.
